Karla Rosalia Sanchez Lievanos and Emmanuel M. Nsengiyumva will conduct research and outreach on ‘forever chemicals’ and carbon capture technology, respectively.
Researchers use $2.4 million grant for dendritic cell cancer immunotherapy; will study hybrid drug delivery vehicle that breaks through intracellular traffic jams.